Celljevity's innovative approach to making advanced cellular therapies accessible to broader populations through strategic partnerships and global expansion.
Revolutionary cellular reprogramming technology shows promising results in reversing biological aging markers and restoring cellular function.
CEO Diederik van der Reijt discusses Celljevity's vision for revolutionizing healthcare through cellular therapy and the company's ambitious growth plans.
Former trader turned biotech entrepreneur Diederik van der Reijt leads breakthrough developments in cellular rejuvenation technology at Celljevity.
Medical Disclaimer: Celljevity's Prometheus technology is currently investigational and not approved by the FDA. Treatment availability varies by jurisdiction. Individual results may vary. Please consult with your healthcare provider. The statements on this website have not been evaluated by the Food and Drug Administration. Our treatments are not intended to diagnose, treat, cure, or prevent any disease.